2022
IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial
Kohli N, Lerner M, Rashty J, Kirke D, Stewart T, Blitzer A. IncobotulinimtoxinA (Xeomin) for the treatment of adductor laryngeal dystonia: A prospective, open-label clinical trial. American Journal Of Otolaryngology 2022, 43: 103613. PMID: 36055061, DOI: 10.1016/j.amjoto.2022.103613.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOpen-label clinical trialProspective open-label trialAdductor laryngeal dystoniaOpen-label trialFirst-line treatmentVoice Handicap Index-10Side effect profileTransient side effectsNormal functionVHI-10 scoresIncobotulinumtoxinA injectionsEffect profileLine treatmentSystemic diseaseTA muscleBotulinum toxinClinical trialsLaryngeal dystoniaNursing womenThyroarytenoid muscleInjection sessionsExclusion criteriaSide effects
2016
Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia
Lerner MZ, Lerner BA, Patel AA, Blitzer A. Gender differences in onabotulinum toxin A dosing for adductor spasmodic dysphonia. The Laryngoscope 2016, 127: 1131-1134. PMID: 27633917, DOI: 10.1002/lary.26265.Peer-Reviewed Original ResearchConceptsAdductor spasmodic dysphoniaSpasmodic dysphoniaOnabotulinum toxinChart reviewFemale groupOnabotulinum Toxin A InjectionsRetrospective chart reviewBotulinum toxin injectionSenior author's databaseAbductor spasmodic dysphoniaIndependent sample twoA injectionAverage followSymptom controlOromandibular dystoniaToxin injectionFemale patientsRetrospective reviewAlternate diagnosisBotulinum toxinAntibody formationFemale genderPossible inverse relationshipInclusion criteriaThyroarytenoid muscle
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply